Flexcompute is collaborating with Starlab Space and Voyager Technologies to simulate cabin airflow inside Starlab, a commercial space station set to succeed the ISS. Using GPU-native CFD tools, Flexcompute modeled airflow and carbon dioxide circulation to optimize Starlab's life support system before launch. This simulation is crucial because airflow behaves differently in microgravity, impacting crew comfort and safety. The partnership accelerates design confidence and advances commercial space station development.
Flexcompute's collaboration on space station life support simulation is the subject. For readers following the Technology sector, here is Pluang's market snapshot as of Oct 06, 2026 19:01 WIB: 132 of 150 US tech stocks rose. Zscaler Inc (ZS) rose 2.33% to USD 206.50 with 100% buy orders and a typical hold time of 41 days. Palo Alto Networks Inc (PANW) rose 2.20% to USD 415.70 with a 47% sell and 53% buy split and 82 days typical hold time. SAP SE (SAP) rose 2.16% to USD 212.22 with 100% buy orders and 118 days typical hold time.
Over the past six months, Costco's stock has fallen by 10%, contrasting with the S&P 500's 17% gain. This decline has sparked debate on whether Costco's shares, now trading under $900, represent a buying opportunity. Investors are weighing if the pri...
Expedia's shares fell over 20% even though the company reported a 14% increase in Q2 sales and a 23% rise in adjusted EBITDA. Management also raised its future guidance, supported by strong B2B bookings exceeding $10 billion and international growth....
ServiceNow's stock has dropped 25% over the past year amid sector-wide software selloffs and profit declines due to acquisitions and rising costs. However, Bernstein analyst Peter Weed projects an 82% price surge to $248, driven by strong growth in g...
Elon Musk's net worth surpassed $1 trillion following a 15% rise in SpaceX shares over two trading sessions, driven by an analyst's bullish note and institutional underweight positioning. Despite the rally, SpaceX shares remain 24% below their June p...
OKYO Pharma has enrolled the first patients in its Phase 3 NEPTUNE trial testing urcosimod for neuropathic corneal pain, a severe eye condition with no FDA-approved treatment. The trial has begun in the US and will expand to Europe, with patients rec...
